• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Dynavax Technologies Corporation

    11/14/24 12:18:08 PM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DVAX alert in real time by email
    SC 13G 1 dvax_111424.htm KYNAM CAPITAL MANAGEMENT, LP dvax_111424.htm
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    SCHEDULE 13G
    Under the Securities Exchange Act of 1934
    Dynavax Technologies Corp.
    (Name of Issuer)
    Common Stock, par value $0.001 per share
    (Title of Class of Securities)
    268158201
    (CUSIP Number)
    September 30, 2024
    (Date of Event which Requires Filing of this Statement)
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    [X] Rule 13d-1(b)
    [   ] Rule 13d-1(c)
    [   ] Rule 13d-1(d)
    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see Instructions).
    CUSIP No.: 268158201
           
    1
    NAME OF REPORTING PERSON
    Kynam Capital Management, LP
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
    85-3660072
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) [   ]
    (b) [   ]
    3 SEC USE ONLY
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5
    SOLE VOTING POWER
    6
    SHARED VOTING POWER
    8,332,687
    7
    SOLE DISPOSITIVE POWER
    8
    SHARED DISPOSITIVE POWER
    8,332,687
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    8,332,687
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    [   ]
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    6.34%
    12
    TYPE OF REPORTING PERSON
    IA
    CUSIP No.: 268158201
           
    1
    NAME OF REPORTING PERSON
    Kynam Capital Management GP, LLC
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
    85-3678691
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) [   ]
    (b) [   ]
    3 SEC USE ONLY
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5
    SOLE VOTING POWER
    6
    SHARED VOTING POWER
    8,332,687
    7
    SOLE DISPOSITIVE POWER
    8
    SHARED DISPOSITIVE POWER
    8,332,687
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    8,332,687
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    [   ]
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    6.34%
    12
    TYPE OF REPORTING PERSON
    OO
    CUSIP No.: 268158201
           
    1
    NAME OF REPORTING PERSON
    Yue Tang
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) [   ]
    (b) [   ]
    3 SEC USE ONLY
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
    U.S.
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5
    SOLE VOTING POWER
    6
    SHARED VOTING POWER
    8,332,687
    7
    SOLE DISPOSITIVE POWER
    8
    SHARED DISPOSITIVE POWER
    8,332,687
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    8,332,687
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    [   ]
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    6.34%
    12
    TYPE OF REPORTING PERSON
    IN
    CUSIP No.: 268158201
    ITEM 1(a). NAME OF ISSUER:
    Dynavax Technologies Corp.
    ITEM 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
    2100 Powell St, Emeryville, CA 94608
    ITEM 2(a). NAME OF PERSON FILING:
    Kynam Capital Management, LP
    Kynam Capital Management GP, LLC
    Yue Tang
    ITEM 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
    221 Elm Road. Princeton, NJ 08540
    ITEM 2(c). CITIZENSHIP:
    Delaware
    Delaware
    U.S.
    ITEM 2(d). TITLE OF CLASS OF SECURITIES:
    Common Stock, par value $0.001 per share
    ITEM 2(e). CUSIP NUMBER:
    268158201
    ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO SECTION 240.13d-1(b), or 13d-2(b) or (c) CHECK WHETHER THE PERSON FILING IS A:
    (a)
    [ ]
    Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78c);
    (b)
    [ ]
    Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)
    [ ]
    Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)
    [ ]
    Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);
    (e)
    [X]
    An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E);
    (f)
    [ ]
    An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F);
    (g)
    [ ]
    A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G);
    (h)
    [ ]
    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)
    [ ]
    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)
    [ ]
    A non-U.S. institution in accordance with 240.13d-1(b)(1)(ii)(J);
    (k)
    [ ]
    Group, in accordance with 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with 240.13d1(b)(1)(ii)(J), please specify the type of institution:
    ITEM 4. OWNERSHIP
    (a) Amount beneficially owned:
    8,332,687
    (b) Percent of class:
    6.34%
    (c) Number of shares as to which the person has:
    (i) sole power to vote or to direct the vote:
    Kynam Capital Management, LP :

    Kynam Capital Management GP, LLC :

    Yue Tang :
    (ii) shared power to vote or to direct the vote:
    Kynam Capital Management, LP : 8,332,687

    Kynam Capital Management GP, LLC : 8,332,687

    Yue Tang : 8,332,687
    (iii) sole power to dispose or direct the disposition of:
    Kynam Capital Management, LP :

    Kynam Capital Management GP, LLC :

    Yue Tang :
    (iv) shared power to dispose or to direct the disposition of:
    Kynam Capital Management, LP : 8,332,687

    Kynam Capital Management GP, LLC : 8,332,687

    Yue Tang : 8,332,687
    ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].
    ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:
    ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY:
    ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP:
    ITEM 9. NOTICE OF DISSOLUTION OF GROUP:
    ITEM 10. CERTIFICATION:
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
    CUSIP No.: 268158201
    SIGNATURE
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
    November 14 2024
    Kynam Capital Management, LP By: Kynam Capital Management GP, LLC, its General Partner
    By:
    /s/ Yue Tang
    Name:
    Yue Tang
    Title:
    Managing Member
    November 14 2024
    Kynam Capital Management GP, LLC
    By:
    /s/ Yue Tang
    Name:
    Yue Tang
    Title:
    Managing Member
    November 14 2024
    Yue Tang
    By:
    /s/ Yue Tang
    Name:
    Yue Tang
    Title:
    Attention — Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001).
    Get the next $DVAX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DVAX

    DatePrice TargetRatingAnalyst
    2/11/2025$15.00 → $12.00Neutral → Sell
    Goldman
    2/1/2024$20.00Neutral
    Goldman
    9/27/2022$22.00Mkt Outperform
    JMP Securities
    1/6/2022$38.00Buy
    Goldman
    12/29/2021$23.00 → $28.00Buy
    HC Wainwright & Co.
    8/31/2021$20.00 → $23.00Buy
    HC Wainwright & Co.
    8/6/2021$19.00Buy
    Goldman Sachs
    8/5/2021$16.00 → $20.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $DVAX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Dynavax downgraded by Goldman with a new price target

      Goldman downgraded Dynavax from Neutral to Sell and set a new price target of $12.00 from $15.00 previously

      2/11/25 7:05:05 AM ET
      $DVAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Goldman initiated coverage on Dynavax with a new price target

      Goldman initiated coverage of Dynavax with a rating of Neutral and set a new price target of $20.00

      2/1/24 6:20:13 AM ET
      $DVAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • JMP Securities initiated coverage on Dynavax with a new price target

      JMP Securities initiated coverage of Dynavax with a rating of Mkt Outperform and set a new price target of $22.00

      9/27/22 7:39:04 AM ET
      $DVAX
      Biotechnology: Pharmaceutical Preparations
      Health Care